Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BMI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,042 result(s) found for: BMI. Displaying page 1 of 153.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-004919-11 Sponsor Protocol Number: FLAIR-i Start Date*: 2022-05-03
    Sponsor Name:Donders Institute for Brain, Cognition and Behaviour, Radboud University
    Full Title: The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study.
    Medical condition: Low-grade inflammation in obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006352-36 Sponsor Protocol Number: VPN-10-18 Start Date*: 2013-04-11
    Sponsor Name:Lithuanian University of Health Sciences, Endocrinology Department
    Full Title: Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evalua...
    Medical condition: The aim of our study is to establish the effectivenes and safety of metformin use in pediatric obese population; to assess the prevalence of insulin resistance, metabolic syndrome, polycystic ovary...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000775-42 Sponsor Protocol Number: RIMON_L_00075 Start Date*: 2007-12-27
    Sponsor Name:University Hospital Tübingen
    Full Title: Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial
    Medical condition: overweight, obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001049-24 Sponsor Protocol Number: NN8022-1839 Start Date*: 2008-12-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002274-31 Sponsor Protocol Number: U1111-1215-8606 Start Date*: 2020-12-16
    Sponsor Name:Department of Biomedical Sciences, University of Copenhagen
    Full Title: Young adults with early-onset obesity treated with semaglutide
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029885 Obesity, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000907-13 Sponsor Protocol Number: 2007-24-001 Start Date*: 2007-11-13
    Sponsor Name:MUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel
    Full Title: The impact of Rimonabant in overweight women with prior gestational diabetes
    Medical condition: Rimonabant has been shown to reduce body weight and improve cardiovascular risk factors and metabolic control. Therefore we investigate in women with previous gestational diabetes and impaired glu...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight LLT
    9.1 10058110 Dyslipidemia LLT
    9.1 10051361 Adipositas LLT
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005628-16 Sponsor Protocol Number: Uni-Koeln-1473 Start Date*: 2012-08-06
    Sponsor Name:University of Cologne
    Full Title: FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients
    Medical condition: Obesity with BMI ≥ 30kg/m²
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002199-88 Sponsor Protocol Number: NN8022-1922 Start Date*: 2008-12-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003380-35 Sponsor Protocol Number: EX9536-4388 Start Date*: 2018-10-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DK (Completed) FI (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) LV (Completed) NL (Completed) CZ (Completed) HU (Completed) BE (Completed) AT (Completed) SE (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date*: 2023-05-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
    Medical condition: Overweight and Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010116-15 Sponsor Protocol Number: CTU 052 D Start Date*: 2010-05-31
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 40 kg/m² or diet-related obesity diagnosed by BMI of 27 to 40 kg/m² in patient with coexisting risk factors like hyperlipidaemia, type 2 diabetes mell...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003426-24 Sponsor Protocol Number: CTU079G Start Date*: 2013-02-13
    Sponsor Name:Riemser Pharma GmbH
    Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-004107-32 Sponsor Protocol Number: RM-493-030 Start Date*: 2023-01-23
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects with Hypothalamic Obesity
    Medical condition: Hypothalamic Obesity
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002868-14 Sponsor Protocol Number: CLIK066B2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee...
    Medical condition: change in weight in obese or overweight adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000882-41 Sponsor Protocol Number: NN9535-4984 Start Date*: 2022-07-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study
    Medical condition: Diabetes Mellitus, Type 2 Overweight
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GR (Trial now transitioned) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004415-37 Sponsor Protocol Number: NN8022-4179 Start Date*: 2015-11-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week dou...
    Medical condition: Obesity (Prader-Willi syndrome)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003940-61 Sponsor Protocol Number: MINT Start Date*: 2020-12-07
    Sponsor Name:Uppsala county council
    Full Title: Metformin Intervention in children and adolescents with obesity. A parallel, three arms, randomized, 6 months, multi-center study with metformin extended release (XR) plus lifestyle or metformin i...
    Medical condition: Children and Adolscents with obesity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003726-32 Sponsor Protocol Number: NN9536-4378 Start Date*: 2018-08-22
    Sponsor Name:Novo Nordisk A/S
    Full Title: Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
    Medical condition: Obesity Overweight
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002953-11 Sponsor Protocol Number: NN9932-4737 Start Date*: 2021-06-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity
    Medical condition: Obesity Overweight
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001731-40 Sponsor Protocol Number: UMCN-ONCO-201301 Start Date*: 2013-08-26
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Influence of exceptional patient characteristics on everolimus exposure
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 19:10:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA